INTEGRATED BIOPHARMA INC
No SEC Form 4 filings for $INBP in the last 30 days.
See all $INBP insider activity →Integrated BioPharma, Inc. (INBP) reported a 31% revenue decline to $9.8M for Q2 2026 and a 19% drop to $43.9M for the fiscal year, with net losses of $1.4M and $2.8M, respectively. The company attributed the decrease to reduced revenue from its two largest customers, according to its executives.
INTEGRATED BIOPHARMA INC (INBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS RELEASE for September 25, 2026 Contact: Dina Masi, CFO Integrated BioPharma, Inc. investors@ibiopharma.com 888.319.6962 Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2026 HILLSIDE, NEW JERSEY (September 25, 2026) - Integrate
INTEGRATED BIOPHARMA INC (INBP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.2 3 ex_983424.htm EXHIBIT 10.2 CONVERTIBLE LINE OF CREDIT NOTE ex_983424.htm Exhibit 10.2 Convertible Line of Credit Note (Daily SOFR) $250,000.00 June 30, 2026 FOR VALUE RECEIVED , INTEGRATED BIOPHARMA, INC. , with an address at 225 LONG AVE, STE 15, HILLSIDE, NEW JERSEY 0
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning INBP (INTEGRATED BIOPHARMA INC). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent INBP coverage spans earnings and corporate actions.
Earnings miss and revenue drop likely pressure the stock lower.
Earnings miss may pressure the stock lower; loss widening suggests cash‑flow concerns.
The 8-K discloses new financing terms (size, SOFR+250 bps pricing, 12-month conversion window), which can affect near-term liquidity and leverage expectations.
AlphAI scores every news story that mentions INBP with an AI model for sentiment and relevance, and aggregates insider trades from INTEGRATED BIOPHARMA INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Integrated BioPharma, Inc. (INBP) reported a 31% revenue decline to $9.8M for Q2 2026 and a 19% drop to $43.9M for the fiscal year, with net losses of $1.4M and $2.8M, respectively. The company attributed the decrease to reduced revenue from its two largest customers, according to its executives.
2 min readINTEGRATED BIOPHARMA INC (INBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS RELEASE for September 25, 2026 Contact: Dina Masi, CFO Integrated BioPharma, Inc. investors@ibiopharma.com 888.319.6962 Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2026 HILLSIDE, NEW JERSEY (September 25, 2026) - Integrate
2 min readINTEGRATED BIOPHARMA INC (INBP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.2 3 ex_983424.htm EXHIBIT 10.2 CONVERTIBLE LINE OF CREDIT NOTE ex_983424.htm Exhibit 10.2 Convertible Line of Credit Note (Daily SOFR) $250,000.00 June 30, 2026 FOR VALUE RECEIVED , INTEGRATED BIOPHARMA, INC. , with an address at 225 LONG AVE, STE 15, HILLSIDE, NEW JERSEY 0
3 min read